Aurinia Pharmaceuticals Inc (AUPH)
PHARMACEUTICAL PREPARATIONS
- Headquarters
- United States
- Employees
- 128
- Market Cap
- $1.9B
About Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.
SentiSense also tracks daily options readings for Aurinia Pharmaceuticals Inc: IV rank, put/call percentile, 25-delta skew, open-interest walls, and unusually active contracts, each measured against the stock's own history. Sign in to view them.
Aurinia Pharmaceuticals Inc stock analysis, sentiment tracking, and market intelligence on SentiSense.